Full Text
Full text is available in PDF
Official Journal of Research Center for Gastroenterology and Liver Diseases
e-ISSN 1735-3408
p-ISSN 1735-143X
Peginterferon alfa-2a and Ribavirin in Patients with Chronic Hepatitis C and Inherited Bleeding Disorders
Authors
Shahin Merat1, Amir Ali Sohrabpour1, Siamak Khaleghi1, Masoud Reza Sohrabi1, Katayon Samimi Rad1, Amir Reza Radmard1, Reza Malekzadeh2,*
1Digestive Disease Research Center, Tehran University of Medical Sciences & Study Group of Interferon in Iran (SG.IFN.IR), Tehran, IR.Iran
2Digestive Disease Research Center, Tehran University of Medical Sciences & Study Group of Interferon in Iran (SG.IFN.IR), malek@ams.ac.ir, Tehran, IR.Iran
*Corresponding Author: Digestive Disease Research Center, Tehran University of Medical Sciences & Study Group of Interferon in Iran (SG.IFN.IR), malek@ams.ac.ir, Tehran, IR.Iran. Tel: 0098 21 801 2992. Fax: 0098 21 225 3635. Email: malek@ams.ac.ir
How to Cite:Merat S, Sohrabpour A, Khaleghi S, Sohrabi M, Rad K, et al. Peginterferon alfa-2a and Ribavirin in Patients with Chronic Hepatitis C and Inherited Bleeding Disorders. Hepat Mon. 2004;4(7):. doi:
Abstract
Background: Patients with inherited bleeding disorders who regularly receive clotting factors are frequently infected with hepatitis C virus (HCV). Liver biopsy in these patients is high-risk and not always performed. There is no report on pegylated interferon (PEG-IFN) and ribavirin in patients with bleeding disorders in whom no histologic data is available.
Aim: To assess the safety and efficacy of combined PEG-IFN alfa-2a and ribavirin in patients with inherited bleeding disorders and hepatitis C.
Methods: We studied 37 patients with inherited bleeding disorders and HCV infection. Patients where planned to receive pegylated interferon alfa 2a (PEG-IFN alfa-2a) 180micg weekly and ribavirin 800mg daily for 48 weeks. They were then followed for 24 weeks after the end of treatment.
Results: Early virologic response at week 12 of treatment was achieved in 31/34 patients (91%) and end-of-treatment response was achieved in 30/31 patients (97%). Sustained virologic response was 26/32 (81%) and 26/35 (74%) on per-protocol and intention-to-treat analysis respectively. Dose reduction due to adverse effects was necessary in 11 patients.
Conclusion: The combination of PEG-IFN alpha 2a and ribavirin is safe and highly effective in patients with inherited bleeding disorders and HCV infection, even when histologic data is absent.
Highlights
Copyright
© 2004, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Similar Articles
30
Sep
2004
Peginterferon Alfa-2a (Pegasys) and Ribavirin in the Treatment of Chronic Hepatitis C
Mohammad Reza Zali,
Hamid Mohaghegh Shalmani,
Mohsen Norouzinia,
Amir Hooshang MohammadAlizadeh,
Azita Nowroozi,
Negar Behrouz
Zali M, Shalmani H, Norouzinia M, MohammadAlizadeh A, Nowroozi A, et al. Peginterferon Alfa-2a (Pegasys) and Ribavirin in the Treatment of Chronic Hepatitis C. Hepat Mon. 2004;4(7):. doi:
30
Sep
2004
The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial
Nasser Ebrahimi Daryani,
Babak Haghpanah,
Ali Reza Sayyah,
Ali Asad Hashtroudi,
Mohammad Bashashati,
Parisa Poursamimi
,et al.Daryani N, Haghpanah B, Sayyah A, Hashtroudi A, Bashashati M, et al. The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial. Hepat Mon. 2004;4(7):. doi:
1
Jan
2015
Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1
Heidar Sharafi,
Seyed Moayed Alavian,
Maryam Keshvari
Sharafi H, Alavian SM, Keshvari M. Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1. Hepat Mon. 2015;15(1):e24955. doi: https://doi.org/10.5812/hepatmon.24955
30
Sep
2004
The Efficacy and Safety of Peginterferon Alpha-2a (PEGASYS) monotherapy in the Treatment of Chronic Hepatitis C Infected Subjects with Transfusion Dependent Thalassemia
Shahram Mirmomen,
Naser Ebrahimi Daryani,
Reza Malekzadeh,
Mohammad Reza Zali,
Babak Haghpanah,
Parisa Poursamimi
,et al.Mirmomen S, Daryani N, Malekzadeh R, Zali M, Haghpanah B, et al. The Efficacy and Safety of Peginterferon Alpha-2a (PEGASYS) monotherapy in the Treatment of Chronic Hepatitis C Infected Subjects with Transfusion Dependent Thalassemia. Hepat Mon. 2004;4(7):. doi:
30
Sep
2004
Efficacy and Safety of Pegylated Interferon Alfa-2a plus Ribavirin for Treatment of Chronic Hepatitis C and Cirrhosis in Iranian
Seyed Moayed Alavian,
Behzad Hajarizadeh,
Bashir Hajibeigi,
Taher Doroudi,
Amir Kambiz Hamadanizadeh,
Koroush Abar
Alavian S, Hajarizadeh B, Hajibeigi B, Doroudi T, Hamadanizadeh A, et al. Efficacy and Safety of Pegylated Interferon Alfa-2a plus Ribavirin for Treatment of Chronic Hepatitis C and Cirrhosis in Iranian. Hepat Mon. 2004;4(7):. doi:
Cited by
- Scopus by DOI: 0
Last Update: 3 weeks ago
- Scopus by Title: 0
Last Update: 3 weeks ago
- Scopus by Title (Ref): 3
Last Update: 3 weeks ago
- CrossRef: 0
Last Update: 4 hours ago
- OpenAlex: 0
Last Update: 6 hours ago
- OpenCitations: 0
Last Update: 4 days ago
Comments
Number of Comments:0